SCHEMBL4285060

SCHEMBL4285060

NC1=NC(N)(c2ccc3c(c2)OCO3)C=C(c2cc(Cl)ccc2Cl)N1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK3 O43781 1/20 0.36
PIM1 P11309 1/20 0.36
CSNK2A2 P19784 1/20 0.36
CSNK2B P67870 1/20 0.36
CSNK2A1 P68400 1/20 0.36
DYRK1A Q13627 1/20 0.36
CSNK2A3 Q8NEV1 1/20 0.36
DYRK2 Q92630 1/20 0.36
DYRK1B Q9Y463 1/20 0.36
CYP19A1 P11511 1/20 0.35
MAOA P21397 1/20 0.34
MAOB P27338 1/20 0.34
MAP2K4 P45985 1/20 0.34
AR P10275 1/20 0.34
NPC1 O15118 5/20 0.33
RAB9A P51151 5/20 0.33
KMT2A Q03164 4/20 0.33
SMN1; SMN2 Q16637 3/20 0.33
MAPT P10636 3/20 0.33
SCN9A Q15858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4289207 0.87 MAPT (0.43) DYRK3PIM1CSNK2A2CSNK2BCSNK2A1
SCHEMBL4280058 0.84 HTR2B (0.39) SMN1; SMN2MAPTLMNAALDH1A1
SCHEMBL4285195 0.79 HTR2B (0.35) ALDH1A1
SCHEMBL4281458 0.78 TMPRSS4 (0.34) KMT2ASLC6A3ALDH1A1MEN1
SCHEMBL4285066 0.75 DYRK3 (0.35) DYRK3PIM1CSNK2A2CSNK2BCSNK2A1
SCHEMBL4285021 0.72 SCN2A (0.33) SMN1; SMN2MAPTSCN9AKDM4ELMNA
SCHEMBL4291033 0.69 AGPAT2 (0.43)
SCHEMBL4282568 0.68 ALDH1A1 (0.41) CYP19A1KMT2AKDM4ELMNAALDH1A1
SCHEMBL4282210 0.67 HTR6 (0.33)
SCHEMBL4286109 0.66 MAP4K4 (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7419984-B2 Pyrimidines and uses thereof CELL THERAPEUTICS, INC. (US) 2008-09-02 US claimed
US-20090099183-A1 PYRIMIDINES AND USES THEREOF CELL THERAPEUTICS, INC. (US) 2009-04-16 US disclosed
US-7419984-B2 Pyrimidines and uses thereof CELL THERAPEUTICS, INC. (US) 2008-09-02 US disclosed
US-20040204386-A1 Pyrimidines and uses thereof CELL THERAPEUTICS, INC. 2004-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040204386-A1 Pyrimidines and uses thereof LPCAT3, LPCAT1, APRT DYRK3 3855/4885PIM1 2928/4885CSNK2A2 3918/4885
US-20090099183-A1 PYRIMIDINES AND USES THEREOF LPCAT3, LPCAT1, APRT DYRK3 4098/4885PIM1 2817/4885CSNK2A2 3497/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.